TELESTA THERAPEUTICS Trademark

Trademark Overview

On Wednesday, December 3, 2014, a trademark application was filed for TELESTA THERAPEUTICS with the United States Patent and Trademark Office. The USPTO has given the TELESTA THERAPEUTICS trademark a serial number of 86469894. The federal status of this trademark filing is ABANDONED - FAILURE TO RESPOND OR LATE RESPONSE as of Tuesday, March 13, 2018. This trademark is owned by Telesta Therapeutics Inc.. The TELESTA THERAPEUTICS trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations, namely, biological and small molecule therapeutics and preventatives for the treatment and prevention of cancer, infectious diseases, auto-immune disease and other human disease conditions
telesta therapeutics

General Information

Serial Number86469894
Word MarkTELESTA THERAPEUTICS
Filing DateWednesday, December 3, 2014
Status602 - ABANDONED - FAILURE TO RESPOND OR LATE RESPONSE
Status DateTuesday, March 13, 2018
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateNOT AVAILABLE

Trademark Statements

Disclaimer with Predetermined Text"THERAPEUTICS"
Goods and ServicesPharmaceutical preparations, namely, biological and small molecule therapeutics and preventatives for the treatment and prevention of cancer, infectious diseases, auto-immune disease and other human disease conditions

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateWednesday, December 10, 2014
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NameTelesta Therapeutics Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressPoint Claire, QC H9R1A3
CA

Trademark Events

Event DateEvent Description
Tuesday, March 13, 2018ABANDONMENT NOTICE MAILED - FAILURE TO RESPOND
Tuesday, March 13, 2018ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE
Tuesday, August 15, 2017NOTIFICATION OF INQUIRY AS TO SUSPENSION E-MAILED
Tuesday, August 15, 2017INQUIRY TO SUSPENSION E-MAILED
Tuesday, August 15, 2017SUSPENSION INQUIRY WRITTEN
Wednesday, February 15, 2017NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
Wednesday, February 15, 2017LETTER OF SUSPENSION E-MAILED
Wednesday, February 15, 2017SUSPENSION LETTER WRITTEN
Monday, August 15, 2016NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
Monday, August 15, 2016LETTER OF SUSPENSION E-MAILED
Monday, August 15, 2016SUSPENSION LETTER WRITTEN
Saturday, August 13, 2016TEAS/EMAIL CORRESPONDENCE ENTERED
Saturday, August 13, 2016CORRESPONDENCE RECEIVED IN LAW OFFICE
Tuesday, August 9, 2016TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED
Thursday, February 25, 2016NOTIFICATION OF INQUIRY AS TO SUSPENSION E-MAILED
Thursday, February 25, 2016INQUIRY TO SUSPENSION E-MAILED
Thursday, February 25, 2016SUSPENSION INQUIRY WRITTEN
Tuesday, August 25, 2015NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
Tuesday, August 25, 2015LETTER OF SUSPENSION E-MAILED
Tuesday, August 25, 2015SUSPENSION LETTER WRITTEN
Monday, August 24, 2015TEAS/EMAIL CORRESPONDENCE ENTERED
Monday, August 24, 2015CORRESPONDENCE RECEIVED IN LAW OFFICE
Monday, August 17, 2015ASSIGNED TO LIE
Thursday, July 30, 2015TEAS RESPONSE TO OFFICE ACTION RECEIVED
Friday, March 20, 2015NOTIFICATION OF NON-FINAL ACTION E-MAILED
Friday, March 20, 2015NON-FINAL ACTION E-MAILED
Friday, March 20, 2015NON-FINAL ACTION WRITTEN
Wednesday, March 18, 2015ASSIGNED TO EXAMINER
Wednesday, December 10, 2014NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM

Related Keywords

therapeutics telesta disease auto diseases infectious immune cancer human other conditions prevention